Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track IAM with free AI briefings, catalyst countdowns, and dilution alerts.

IAM · Iambic Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$207.9M Cash on Hand

38mo Cash Runway

Follow IAM by email Get an email when IAM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IAM, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Oct 16, 2026 · Iambic Therapeutics filed amended and restated certificate of incorporation and bylaws on October 16, 2026, in connection with completing its IPO. Full terms are in the referenced prospectus and exhibits.
Form 8-K · SEC filing

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

Dec 2027 · Phase 1 · Recruiting · A Phase 1/1b Study of IAM1363 in HER2 Cancers
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
HER2 Inhibitor IAM1363	HER2 Mutation-Related Tumors	Phase 1 · NCT06253871	Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IAM holds $207.9M in cash and short-term investments and burns about $16.4M/quarter from operations, an estimated runway of 38 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Cash runway 38 months
S-1 registration (Sep 2026) +8

Recent financing filings on SEC EDGAR:

Oct 15, 2026 · Underwritten offering, $150M · 424B4
Sep 21, 2026 · S-1 registration · S-1

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IAM files for a raise →

Get the full IAM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IAM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z